Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04129944 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee
A Phase 2 study, sponsored by Unity Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT04129944 is a Phase 2 study that has completed, run by Unity Biotechnology. The registered enrollment target is 183 participants.
The verdict
NCT04129944, a Phase 2 study, has completed, sponsored by Unity Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
Interventions
- OTHER Placebo
- DRUG UBX0101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2020-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04129944
The ClinicalTrials.gov registry entry for NCT04129944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Unity Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04129944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04129944 about?
NCT04129944 is a clinical study titled "A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee". A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
What is the current status of trial NCT04129944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2019-10-30. Estimated completion is 2020-08-07.
What interventions are being tested in trial NCT04129944?
The interventions under investigation include: Placebo (OTHER), UBX0101 (DRUG).
Who is sponsoring clinical trial NCT04129944?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.